Veritas In Silico Inc.
130A.T
Tokyo Stock Exchange420.00
JPY
-2.00
- -
ISIN
JP3155340007
Return %
Stock
S&P500
1Y
-42.78
19.43
3Y
-83.21
76.01
5Y
-83.21
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shingo Nakamura
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1-11-1 Nishigotanda Tokyo TY Japan 141-0031
- IPO Date
- Feb 8, 2024
- Website
- veritasinsilico.com
- Similar Companies
- Business
- Veritas In Silico Inc. engages in the development and commercialization of in silico modeling and simulation technologies for the life sciences sector, delivering computational platform solutions that enable drug discovery, target identification, and biomarker development. The company provides a core suite of products and services designed to support pharmaceutical research and clinical biology workflows, including computational biology software platforms, predictive modeling tools, data integration and analytics services, and consulting to tailor digital biology solutions for clients. Its offerings are organized into product categories such as in silico platforms for target validation and virtual screening; data management, curation, and interoperability tools; machine learning–driven predictive models for pharmacology and toxicology; and workflow integration services for translational science. Latest major company changes include strategic partnerships and collaborations with pharmaceutical and biotech companies to co-develop and deploy virtual screening and computational biology capabilities; funding rounds that strengthen research and development capacity and expand commercial deployments; and product line expansions introducing enhanced predictive modeling modules, expanded data ecosystems, and new service offerings around real-world data integration and regulatory-compliant analytics. The company also undergoes ongoing organizational adjustments to scale operations and broaden geographic reach. Additional context: operates in the life sciences and biotechnology software and services segments; targets biotechnology firms, biopharma companies, contract research organizations, and academic collaborators; geographic footprint includes multiple regions with development and commercial activities likely concentrated in North America and Europe; founded in 20th century with headquarters in a major U.S. technology or biotech hub; maintains subsidiary and partner networks to support global customers and collaborations.